Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998764 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 494
- Enrollment target
NCT00998764 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 494 participants.
The verdict
NCT00998764, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 494 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.
Interventions
- DRUG Bapineuzumab 0.5 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00998764
The ClinicalTrials.gov registry entry for NCT00998764 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bapineuzumab 0.5 mg/kg is the first listed.
NCT00998764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00998764 about?
NCT00998764 is a clinical study titled "A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients". The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation w...
What is the current status of trial NCT00998764?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 494 participants. The study started on 2009-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00998764?
The interventions under investigation include: Bapineuzumab 0.5 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00998764?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.